Clinical Trial

A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 22, 2026 (before its estimated April 23, 2026 completion). Its status may not reflect the trial's current state.
Summary
Mucosal-specific sIgA antibody GMT;Evaluate the achievement of 2-fold and 4-fold increases in the geometric mean titer (GMT) of specific nasal mucosal sIgA antibodies after vaccination
Trial Details
NCT Number NCT07545564
Lead Sponsor Changchun BCHT Biotechnology Co.
Conditions Influenza
Enrollment 200 participants
Start Date 2026-04-09
Primary Completion 2026-04-23 (estimated)
Study Completion 2026-05-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-22